{"id":"NCT00306384","sponsor":"Takeda","briefTitle":"Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus","officialTitle":"A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2006-03-23","resultsPosted":"2013-03-22","lastUpdate":"2013-03-22"},"enrollment":3323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR110322","SYR-322"]}],"arms":[{"label":"Alogliptin 12.5 mg","type":"EXPERIMENTAL"},{"label":"Alogliptin 25 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"4 years","effectByArm":[{"arm":"Alogliptin 12.5 mg","deltaMin":87.2,"sd":null},{"arm":"Alogliptin 25 mg","deltaMin":87.1,"sd":null},{"arm":"Rescued: Alogliptin 25 mg","deltaMin":84.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":114,"countries":["United States","Argentina","Brazil","Chile","Czechia","Dominican Republic","Germany","Guatemala","Netherlands","Peru","Poland","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":233,"n":1394},"commonTop":["Hypertension","Urinary tract infection","Upper respiratory tract infection","Nasopharyngitis","Influenza"]}}